Iodine-123 iomazenil (Iomazenil) is a ligand for central type benzodiazepine receptors that is suitable for single-photon emission tomography (SPET). The purpose of this study was to develop a simple method for the quantification of its binding potential (BP). The method is based on a two-compartment model (K1, influx rate constant; k2', efflux rate constant; V(T)' (= K1/k2'), the total distribution volumes relative to the total arterial tracer concentration), and requires two SPET scans and one blood sampling. For a given input function, the radioactivity ratio of the early to delayed scans can be considered to tabulate as a function of k2' and a table look-up procedure provides the corresponding k2' value, from which K1 and V(T)' values are then calculated. The arterial input function is obtained by calibration of the standard input function by the single blood sampling. SPET studies were performed on 14 patients with cerebrovascular diseases, dementia or brain tumours (mean age ± SD, 56.0 ± 12.2). None of the patients had any heart, renal or liver disease. A dynamic SPET scan was performed following intravenous bolus injection of Iomazenil. A static SPET scan was performed at 180 min after injection. Frequent blood sampling from the brachial artery was performed on all subjects for determination of the arterial input function. Two-compartment model analysis was validated for calculation of the V(T)' value of Iomazenil. Good correlations were observed between V(T)' values calculated by three-compartment model analysis and those calculated by the present method, in which the scan time combinations (early scan/delayed scan) used were 15/180 min, 30/180 min or 45/180 min (all combinations: r = 0.92), supporting the validity of this method. The present method is simple and applicable for clinical use.
- Benzodiazepine receptor
- Iodine-123 iomazenil
- Single-photon emission tomography
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging